Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA.
To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T), natural killer (NK) and T cell receptor (TCR) cell-based approaches that use viral and non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 [email protected] David Pitts Argot Partners 212-600-1902 [email protected]
